Related Directory Categories
- Tacrine (1)
Sources
Help build the largest human-edited directory on the web.
Submit a site - Become an editor
Wikipedia. Licensed under the GNU Free Documentation License.
Are you an expert in this subject? Join the discussion and share your knowledge at Wikipedia.org.
Tacrine
From Wikipedia, the free encyclopedia
 |
|
|
Tacrine
|
|
| Systematic (IUPAC) name | |
| 1,2,3,4-tetrahydroacridin-9-amine | |
| Identifiers | |
| CAS number | |
| ATC code | N06 N06DA01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C13H14N2 |
| Mol. mass | 198.264 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 2.4–36% (oral) |
| Protein binding | 55% |
| Metabolism | Hepatic (CYP1A2) |
| Half life | 2–4 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral, rectal |
Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor (anticholinesterase). It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney.
Tacrine was the prototypical cholinesterase inhibitor for the treatment of Alzheimer's disease. Studies have found that it may have a small beneficial effect on cognition and other clinical measures, though adequate study data is limited and the clinical relevance of these findings is unclear.[1][2]
The use of tacrine is limited by poor oral bioavailability, the necessity for four-times daily dosing, and considerable adverse drug reactions (including nausea, diarrhea, urinary incontinence and hepatotoxicity) such that few patients could tolerate therapeutic doses.[3]
Other newer cholinesterase inhibitors, such as donepezil, are now preferred over tacrine.
- ^ Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA 1998;280(20):1777-82. PMID 9842955
- ^ Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th edition. Edinburgh: Churchill Livingstone; 2003.
- ^ Sweetman S, editor. Martindale: the complete drug reference, 34th ed. London: Pharmaceutical Press; 2004. ISBN 0-85369-550-4
| Anticholinesterases (N06DA, N07AA) edit |
| Metrifonate - Physostigmine - Neostigmine - Pyridostigmine - Ambenonium - Demarcarium - Rivastigmine - Galantamine - Donepezil - Tacrine - Edrophonium |